Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The Ras/Raf/Mek/Erk mitogen-activated protein kinase pathway regulates fundamental processes in normal and malignant cells, including proliferation, differentiation, and cell survival. Mutations in this pathway have been associated with carcinogenesis and developmental disorders, making Mek1 and Mek2 prime therapeutic targets. In this study, we examined the requirement for Mek1 and Mek2 in skin neoplasia using the two-step 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) skin carcinogenesis model. Mice lacking epidermal Mek1 protein develop fewer papillomas than both wild-type and Mek2-null mice following DMBA/TPA treatment. Mek1 knockout mice had smaller papillomas, delayed tumor onset, and half the tumor burden of wild-type mice. Loss of one Mek1 allele, however, did not affect tumor development, indicating that one Mek1 allele is sufficient for normal papilloma formation. No difference in TPA-induced hyperproliferation, inflammation, or Erk activation was observed between wild-type, conditional Mek1 knockout, and Mek2-null mice, indicating that Mek1 findings were not due to a general failure of these processes. These data show that Mek1 is important for skin tumor development and that Mek2 cannot compensate for the loss of Mek1 function in this setting. [Cancer Res 2009;69(9):3772–8]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia
Dajee, M., Lazarov, M., Zhang, J. Y., Cai, T., Green, C. L., Russell, A. J., Marinkovich, M. P., Tao, S., Lin, Q., Kubo, Y., et al. (2003) · Nature · doi:10.1038/nature01283 · Cited by 535 · cited 1×
“This finding is more pronounced in epithelial squamous cell carcinomas (SCC), the majority of which exhibit Ras GTPase activation and MAPK cascade hyperactivation (3, 4).”
BackgroundSelf-citation
Cited by
Targeting the MAPK pathway in KRAS-driven tumors
Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512
Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302
“These results differed from those observed with DMBA-induced skin tumors in which Mek2 could not compensate for the absence of Mek1 (Scholl et al., 2009), further illustrating that the contribution of individual members of the Ras/Mek/Erk pathway is likely to be cell type dependent.”
Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33
“Together, these findings show that many of the MEK1/2-dependent (on-target) extratumoral toxicities (Scholl et al., 2009; Balagula et al., 2011) of MEK inhibition are substantially mitigated by the FeADC approach, which might improve the poor therapeutic index of RAS-RAF-MAPK blockade in the clinic.”
Metadata
- Authors
- Scholl, F. A., Dumesic, P. A., Barragan, D. I., Harada, K., Charron, J., & Khavari, P. A.
- Venue
- Cancer Research
- Published
- 2009-04-30
- Volume
- 69
- Issue
- 9
- Pages
- 3772-3778
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2149516653
- Cited by
- 53
- References
- 1
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-1963
- The paper
- Scholl, F. A., Dumesic, P. A., Barragan, D. I., Harada, K., Charron, J., & Khavari, P. A. (2009). Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-1963
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.